Oramed Initiates NASH Trial of Oral Insulin

Oramed Pharmaceuticals has screened the first patients in a global trial of its oral insulin capsule ORMD-0801 for the treatment of Nonalcoholic steatohepatitis (NASH). The patients were screened at a U.S. site participating in Oramed's trial, being conducted at U.S., EU and Israeli clinical sites.

The trial will be comprised of eight clinical sites: three in the EU, three in the U.S. and two in Israel. The trial will measure efficacy endpoints via MRI-PDFF for 12-weeks dosing.

"Based on the strong results from our previous study, where ORMD-0801 showed a 30% relative reduction in liver fat, we are excited to be starting this important international NASH trial and we look forward to sharing the data as it becomes available," said Oramed CEO Nadav Kidron.